Acino ? Delivering Health
Acino ? Delivering Health
Acino ? Delivering Health
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Development projects<br />
Leuprorelin 1 & 3-month implant<br />
Target indication<br />
– Prostate cancer<br />
<strong>Acino</strong>'s timeline for target markets US and EU/ROW<br />
– Launch EU Q1/Q2-2016<br />
– Launch US Q4-2016<br />
Reference product<br />
– Enantone ® / Trenantone ® (Takeda) → Microparticle formulation<br />
– Implant has potential advantages compared to microparticles:<br />
> Easy preparation of injection (no reconstitution)<br />
> Less painful application<br />
> Less drug burst<br />
> Easier removal in case of adverse reactions<br />
Competitor situation<br />
– Only one implant formulation marketed (not in US)<br />
– Only one competitor with implant in clinical phase<br />
28
Change language